[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
1-Aug-2014

[ | E-mail ] Share Share

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation

CRF announces late-breaking trials and first report investigations for TCT 2014

NEW YORK, NY – August 1, 2014 – The Cardiovascular Research Foundation (CRF) has announced the late-breaking trials and first report investigations that will be presented at next month's Transcatheter Cardiovascular Therapeutics (TCT) 2014 scientific symposium. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will take place September 13 – 17, 2014 at the Walter E. Washington Convention Center in Washington, DC.

Clinical research data presented at TCT often direct the course of patient therapies. The studies selected will examine the effectiveness and safety of minimally invasive techniques, pharmaceuticals, technologies, and devices that show potential to treat or prevent cardiovascular disease, one of the leading causes of death globally.

Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Saturday, September 13; Sunday, September 14; Monday, September 15; and Tuesday, September 16.

Media are invited to attend TCT; press credentials and registration information can be found here: http://www.crf.org/tct/press/press-registration-form.

Saturday, September 13

Plenary Session V: Late-Breaking Clinical Trials I
11:00 AM-12:00 PM

PARTNER I: Five-Year Results From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Balloon-Expandable Device Versus Conservative Care in Extremely High-Risk Patients with Aortic Stenosis
Samir R. Kapadia

US CoreValve High Risk Trial: Cost-Effectiveness Analysis From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Self-Expanding Device Versus Surgical Aortic Valve Replacement in High-Risk Patients with Aortic Stenosis
Matthew R. Reynolds

CLEAN-TAVI: A Prospective, Randomized Trial of Cerebral Embolic Protection in High-Risk Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement
Axel Linke

Plenary Session VI: First Reports I
12:00 PM-12:30 PM

The CoreValve US Pivotal Trial: Two-Year Results with a Self-Expanding Bioprosthesis in Extremely High-Risk Patients with Aortic Stenosis
Steven J. Yakubov

ISAR-CLOSURE: A Prospective, Randomized Trial of Two Vascular Closure Devices Versus Manual Compression After Femoral Artery Access
Stefanie Schulz

Sunday, September 14

Plenary Session XII: Late-Breaking Clinical Trials II
11:00 AM-12:00 PM

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease
Patrick W. Serruys

DKCRUSH-VI: A Prospective, Randomized Trial of FFR-Guided Versus Angiography-Guided Provisional T-Stenting in Patients with True Coronary Bifurcation Lesions
Shao Liang Chen

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents
Fernando Alfonso

Plenary Session XII: First Reports II
12:00 PM-12:30 PM

IVUS-CTO: A Prospective, Randomized Trial of Intravascular Ultrasound-Guided Versus Angiography-Guided Drug-Eluting Stent Intervention in Coronary Chronic Total Occlusions
Yang-Soo Jang

OCT STEMI: A Prospective, Randomized Trial of Optical Coherence Tomography Guidance During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction
Pavel Cervinka

Monday, September 15

Plenary Session XIX: Late-Breaking Clinical Trials III
11:10 AM-12:06 PM

BRIGHT: A Prospective, Randomized Trial of Bivalirudin Monotherapy Versus Heparin Monotherapy Versus Heparin Plus Tirofiban in Patients with Acute Myocardial Infarction Undergoing Coronary Intervention
Yaling Han

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation
Nikolaus Sarafoff

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation
Antonio Colombo

Plenary Session XX: First Reports III
12:06 PM-12:36 PM

TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Tracy Y. Wang

VELOCITY: A Prospective, Randomized Trial of Peritoneal Hypothermia in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Gregg W. Stone

Tuesday, September 16

Plenary Session XXVI: Late-Breaking Clinical Trials IV
11:00 AM-12:00 PM

PRIMA: A Prospective, Randomized Trial of PFO Closure in Patients with Refractory Migraine with Aura
David Hildick-Smith

Symplicity Flex: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension
Steffen Desch

EXCITE ISR: A Prospective, Randomized Trial of Excimer Laser Atherectomy Versus Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis
Eric J. Dippel

Plenary Session XXVII: First Reports IV
12:00 PM-12:30 PM

I-LOVE-IT 2: A Prospective, Randomized Trial of a Biodegradable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent Versus a Durable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent in Patients with Coronary Artery Disease
Yaling Han

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease
Stéphane Cook

###

To view the complete TCT agenda, visit: http://www.crf.org/tct/agenda/tct-program.

Receive updates on Twitter: http://twitter.com/TCTConference

About CRF and TCT

The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with heart disease through high quality research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the world's premier educational meeting specializing in interventional cardiovascular medicine. For more than 25 years, TCT has featured major medical research breakthroughs and gathered leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.

For more information, visit http://www.crf.org and http://www.tctconference.com.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.